![Monica Bertagnolli, first woman and first clinical trials group chair to direct the National Cancer Institute](https://cdn.cancerletter.com/media/2022/07/20123539/Monica-Bertagnolli-4x3-2.jpg)
![Monica Bertagnolli, first woman and first clinical trials group chair to direct the National Cancer Institute](https://cdn.cancerletter.com/media/2022/07/20123539/Monica-Bertagnolli-4x3-2.jpg)
Cover Story
FreeWhite House
By Paul Goldberg and Matthew Bin Han Ong
Monica M. Bertagnolli, a professor of surgery at Harvard Medical School, stands poised to become the first woman and the first chair of a clinical trials cooperative group to be named director of the National Cancer Institute.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages